Product category:
Genomics
News Release from: Transgenomic | Subject: Wave
Edited by the Laboratorytalk Editorial
Team on 05 September 2003
Benefits of Wave reviewed at colorectal
meeting
Advancing the epidemiologic research programmes for the US National Cancer Institute's Colon Cancer Family Registry
Transgenomic announced that the application of its Wave System for DNA analysis will be discussed at the Fourth Joint Meeting of the Leeds Castle Polyposis Group and the International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer This meeting is jointly sponsored by the Cleveland Clinic Foundation and is being held in Cleveland USA on 2-6 September 2003
This article was originally published on Laboratorytalk on 14 Jan 2002 at 8.00am (UK)
Related stories
Old records meet new Wave
Old church records and Transgenomic's Wave nucleic acid fragment analysis system are being brought together in the north of Sweden to investigate a variety of familial diseases
Helping osteoporosis research in Sweden
Researchers are using a nucleic acid fragment analysis system to identify novel genetic polymorphisms linked to osteoporosis and cardiovascular disease
In a presentation to be given at this meeting, Robert Haile, professor and director of the Genetic Epidemiology Program, Department of Preventive Medicine at the University of Southern California's Keck School of Medicine, will discuss use of the Wave System for detection of genetic mutations in individuals with hereditary forms of colorectal cancer.
Haile is a principal investigator affiliated with the Colon Cancer Family Registry (the Colon CFR), a National Cancer Institute-funded international consortium of six research institutions.
These centers and their collaborators are engaged in a cooperative effort to collect pedigree information, epidemiological data and related biological specimens from patients with a family history of colon cancer in order to provide a resource for epidemiologic and translational research.
Further reading
Receptor mutations in clinical specimens
Nuclease used to detect mutations associated with response to therapy in lung cancer; high-sensitivity scanning for epidermal growth factor
Low-level mutation in mast cell leukemia
Transgenomic's Wave System and Surveyor nuclease used for detection and monitoring of low-level mutation in mast cell leukemia; demonstrates highly sensitive detection of disease-associated mutation
According to Haile, "An important goal of the Colon CFR is to test for mutations in the MSH2 and MLH1 genes in over 2,000 subjects with colorectal cancer".
"Most centers in the Colon CFR decided to use DHPLC and the WAVE System from Transgenomic because this technology provides us with a cost-effective, easy-to-use, robust and highly sensitive technique for mutation detection." He continued, "In addition, we like the fact that the Wave System may be used for other research projects that we plan, including DNA or RNA sizing and quantitation, post-PCR fragment purification and collection, and genotyping using primer extension methods or microsatellite DNA analysis." Collin D'Silva, Transgenomic's CEO, stated, "Several Wave Systems have been recently purchased by CFR centers in addition to existing systems at several of these sites".
"We believe our Wave technology is ideal for the analysis of genes such as MSH2 and MLH1, which are characterized by hundreds of different mutations in populations that have been studied to date".
"The Wave System offers a time- and cost-effective means to scan genes of interest for almost all relevant mutations, eliminating the need to design and optimize specific probe- or primer-based tests for each individual mutation." In addition to these recent CFR center installations, the Wave System is in use for colorectal cancer studies at several clinical labs around the world.
• Transgenomic: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
